Pibrentasvir is primarily used in the treatment of chronic hepatitis C virus (HCV) infection. It is a potent NS5A inhibitor that works by blocking the replication of the HCV virus, effectively reducing the viral load in the body. It is often combined with other antiviral agents, such as glecaprevir, to form a highly effective direct-acting antiviral (DAA) regimen. This combination therapy is particularly beneficial for patients with various HCV genotypes, including those who have previously failed other treatments or have compensated cirrhosis. The use of pibrentasvir has significantly improved cure rates, shortened treatment durations, and minimized side effects compared to older HCV therapies. Its application has been a major advancement in achieving sustained virologic response (SVR) and improving the quality of life for patients with hepatitis C.